Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DDRD2HRH1HTR2AHTR2CSLC6A2
The experimentally established mechanism targets of Trimipramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 7/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 6/20 | 1.00 |
| ▸ | HRH1 known ✓ | P35367 | 6/20 | 0.54 |
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.54 |
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 0.54 |
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 0.54 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 9/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 7/20 | 1.00 |
| ▸ | DRD3 | P35462 | 7/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 7/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 6/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 5/20 | 1.00 |
| ▸ | DRD1 | P21728 | 5/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 5/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimipramine SCHEMBL35144 | 1.00 | SLC6A4 (1.00) | SLC6A4CHRM1ADRA1ADRD3KCNH2 | |
| Trimipramine SCHEMBL117756 | 1.00 | SLC6A4 (1.00) | SLC6A4CHRM1ADRA1ADRD3KCNH2 | |
| Trimipramine SCHEMBL5494378 | 1.00 | SLC6A4 (1.00) | SLC6A4CHRM1ADRA1ADRD3KCNH2 | |
| Trimipramine SCHEMBL4081184 | 0.98 | SLC6A4 (0.97) | SLC6A4CHRM1ADRA1ADRD3KCNH2 | |
| Trimipramine SCHEMBL30533075 | 0.98 | SLC6A4 (0.97) | SLC6A4CHRM1ADRA1ADRD3KCNH2 | |
| Trimipramine SCHEMBL7597041 | 0.98 | SLC6A4 (0.97) | SLC6A4CHRM1ADRA1ADRD3KCNH2 | |
| Trimipramine SCHEMBL29564386 | 0.91 | SLC6A4 (0.83) | SLC6A4CHRM1ADRA1ADRD3KCNH2 | |
| Trimipramine SCHEMBL6511858 | 0.90 | CHRM1 (0.82) | SLC6A4CHRM1ADRA1ADRD3KCNH2 | |
| Trimipramine SCHEMBL6511859 | 0.90 | CHRM1 (0.82) | SLC6A4CHRM1ADRA1ADRD3KCNH2 | |
| SCHEMBL2615203 | 0.89 | LMNA (0.80) | SLC6A4CHRM1ADRA1ADRD3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4208466-B1 | HIGH AFFINITY MACROCYCLIC FKB51-INHIBITORS FOR TREATMENT OF PSYCHIATRIC DISORDERS | UNIV DARMSTADT TECH (DE) | 2025-06-11 | — | — | EP | claimed |
| EP-3946296-B9 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2024-12-25 | — | — | EP | claimed |
| EP-4114466-B1 | TREATMENT OF PAIN AND VASOCONSTRICTION | AISA PHARMA INC (US) | 2024-12-04 | — | — | EP | claimed |
| EP-3638673-B9 | TETRAHYDROPYRIDOPYRAZINE MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-20 | — | — | EP | claimed |
| EP-3706762-B1 | N4-HYDROXYCYTIDINE DERIVATIVE AND ANTI-VIRAL USES RELATED THERETO | UNIV EMORY (US) | 2024-10-16 | — | — | EP | claimed |
| EP-3638673-B1 | TETRAHYDROPYRIDOPYRAZINE MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-17 | — | — | EP | claimed |
| EP-3946296-B1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2024-05-01 | — | — | EP | claimed |
| EP-3529229-B1 | POLYMORPHIC FORMS OF SODIUM BENZOATE AND USES THEREOF | SYNEURX INT TAIWAN CORP (TW) | 2024-04-17 | — | — | EP | claimed |
| EP-3641774-B1 | PECTIN GUMMY COMPOSITION AND METHODS OF MAKING AND USING THEREOF | SEATTLE GUMMY COMPANY (US) | 2024-03-27 | — | — | EP | claimed |
| EP-3125893-B1 | DEUTERATED HETEROCYCLE FUSED GAMMA-CARBOLINES AS ANTAGONISTS OF 5-HT2A RECEPTORS | INTRA CELLULAR THERAPIES INC (US) | 2023-09-20 | — | — | EP | claimed |
| EP-3697386-B1 | LIQUID COMPOSITIONS FOR PERORAL USE COMPRISING PHOSPHATIDYLGLYCEROL DERIVATIVES AND THIXOTROPIC EXCIPIENTS FOR TREATING CARDIAC CHANNELOPATHIES CAUSED BY PHARMACOLOGICAL AGENTS | SIGNPATH PHARMA INC (US) | 2023-07-26 | — | — | EP | claimed |
| EP-3436568-B1 | CULTURE MEDIUM FOR PLURIPOTENT STEM CELLS | PROMOCELL GMBH (DE) | 2023-06-14 | — | — | EP | claimed |
| EP-3151837-B1 | PROTECTIVE EFFECT OF DMPC, DMPG, DMPC/DMPG, EGPG, LYSOPG AND LYSOPC AGAINST DRUGS THAT CAUSE CHANNELOPATHIES | SIGNPATH PHARMA INC (US) | 2023-03-15 | — | — | EP | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| US-20260076931-A1 | L-DOPA MICROBIOME THERAPY | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2026-03-19 | — | — | US | disclosed |
| CN-111836798-B | Prodrugs of ketamine, compositions and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2022-04-15 | — | — | CN | disclosed |
| US-11274996-B2 | Compressed open flow assay and use | ESSENLIX CORPORATION (US) | 2022-03-15 | — | — | US | disclosed |
| US-20220031771-A1 | MICROENCAPSULATED AND CHROMOSOME INTEGRATED COMPOSITIONS FOR L-DOPA MICROBIOME THERAPY | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220031771-A1 | MICROENCAPSULATED AND CHROMOSOME INTEGRATED COMPOSITIONS FOR L-DOPA MICROBIOME THERAPY | PARK7, NPY5R, CHRNA5 | ADRA1A 192/4885SLC6A2 155/4885HRH1 423/4885 |
| US-20260076931-A1 | L-DOPA MICROBIOME THERAPY | DDC, MAOB, TPH2 | ADRA1A 281/4885SLC6A2 6/4885HRH1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.